Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan
Oku et al.,
Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a..,
Modern Rheumatology, doi:10.1093/mr/roac104
Retrospecttive 220 COVID-19 patients with rheumatic disease in Japan, showing lower mortality and hospitalization with HCQ prophylaxis, without statistical significance.
risk of death, 92.2% lower, RR 0.08, p = 1.00, treatment 0 of 14 (0.0%), control 11 of 206 (5.3%), NNT 19, unadjusted, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of hospitalization, 11.5% lower, RR 0.88, p = 0.34, treatment 9 of 14 (64.3%), control 177 of 206 (85.9%), NNT 4.6, adjusted per study, odds ratio converted to relative risk, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Oku et al., 6 Sep 2022, retrospective, Japan, peer-reviewed, 8 authors, study period 3 June, 2020 - 30 June, 2021.
Contact:
horiuchi.takahiko.191@m.kyushu-u.ac.jp.
Abstract: MORH-D-22-00049 Received: 20-Jan-2022; Accepted: 4-Aug-2022
Original Article
Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a
nation-wide JCR COVID-19 registry in Japan
Okamoto5), Tatsuya Atsumi6), Tsutomu Takeuchi4) and The member of the JCR-COVID19 patient registry team
1) Department of Rheumatology and Infectious Diseases, Kitasato University, Kanagawa, Japan
2) Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan
3) Department of Rheumatology and Nephrology, Chubu Rosai Hospital, Aichi, Japan
4) Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo,
Japan
5) Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of
Medicine, Osaka, Japan
6) Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of
Medicine, Hokkaido, Japan
*Kenji Oku and Yasutaka Kimoto contributed equally to this article.
Corresponding author: Takahiko Horiuchi,
Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan
Email: horiuchi.takahiko.191@m.kyushu-u.ac.jp
ABSTRACT
Background: The incidence and prognosis of COVID-19 and rheumatic disease vary among ethnicities and
regions. COVID-19 outcomes in rheumatic disease patients remain unclear, especially in the Asia-Pacific region.
This study aimed to clarify the demographic and clinical factors that may influence COVID-19 prognosis in
rheumatic disease patients.
© Japan College of Rheumatology 2022. Published by Oxford University Press.
Kenji Oku1)*, Yasutaka Kimoto2)*, Takahiko Horiuchi2), Mari Yamamoto3), Yasushi Kondo4), Masashi
Methods: This was a case series of patients registered with the COVID-19 national registry of Japan College of
Rheumatology between June 3, 2020, and June 30, 2021. Multivariable logistic regression was used to estimate
the risk of hospitalization or death. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities, and
rheumatic disease medications are taken immediately before infection was analyzed.
Results: A total of 220 patients from 55 institutions in Japan were included in the study, among whom 186
and mainly comprised glucocorticoids, favipiravir, remdesivir, and tocilizumab.
In the multiple logistic regression model, older age and a history of hypertension were associated with
hospitalization, while older age was associated with mortality. No specific treatment was correlated with
mortality or hospitalization by the multi-variate analysis.
Conclusions: Older age and hypertension were associated with a poor prognosis in Japanese COVID-19 patients
with CTD. Factors not directly related to CTD were closely associated with the prognosis.
Keywords: COVID-19, Japan, Rheumatic disease, SARS-CoV2
In December 2019, the report of pneumonia of an unknown cause found in Wuhan, Hubei Province, China
spread out to the world. The infection was found to be caused by a novel coronavirus, severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), and the disease was named Coronavirus Disease 2019 (COVID-19).
COVID-19 spread rapidly all over the world, and on March 11, 2020, the WHO declared a pandemic. In Japan,
the first case was reported on January 15, 2021, and by June 2021, 0.8 million people (6.7% of the..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit